Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 1;40(1):106-107.
doi: 10.1200/JCO.21.01754. Epub 2021 Oct 15.

Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

Affiliations
Comment

Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy

Alfred Garfall et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Alfred GarfallConsulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, AmgenResearch Funding: Novartis, Tmunity Therapeutics, Inc, Janssen Oncology, Crispr TherapeuticsPatents, Royalties, Other Intellectual Property: Patent in the field of CAR-T cell therapy Adam CohenConsulting or Advisory Role: Celgene, Janssen Oncology, Oncopeptides, Takeda, Seattle Genetics, GlaxoSmithKline, Novartis, Bristol Meyers Squibb, AstraZeneca, Roche/GenentechResearch Funding: Novartis, GlaxoSmithKlinePatents, Royalties, Other Intellectual Property: Patents related to CAR-T cells and biomarkers of Cytokine Release SyndromeExpert Testimony: Janssen OncologyTravel, Accommodations, Expenses: GlaxoSmithKline, Takeda, Celgene, Janssen Oncology Edward StadtmauerConsulting or Advisory Role: Celgene, Takeda, Novartis, Teva, Janssen, Amgen, Sanofi Dan VoglConsulting or Advisory Role: Celgene, Karyopharm Therapeutics, Janssen, GlaxoSmithKline, Takeda, CSL Behring, OncopeptidesResearch Funding: Active Biotech, TakedaTravel, Accommodations, Expenses: Takeda, Karyopharm TherapeuticsNo other potential conflicts of interest were reported.

Comment in

Comment on

LinkOut - more resources